Project Grant R01AR083437
Award Date
9/17/24
Completion Date
7/31/29
Dollars Obligated
$393K
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
Nashville, TN 37203, USA
Similar Awards
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $220,224 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to The Regents of the University of Colorado (CU) for the project "GRANULAR HYDROGELS FOR THE CONTROLLED DELIVERY OF IMMUNOMODULATORY AND ANGIOGENIC EXTRACELLULAR VESICLES TO ENHANCE BONE TISSUE REGENERATION". The grant, awarded on July 4, 2024, supports CU's research to develop novel...
This federal Project Grant award of $595,117 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to develop carrier-free siRNA conjugates as potential disease-modifying osteoarthritis drugs. Key objectives include elucidating the mechanism of action of the siRNA-L2 conjugate against MMP13 in osteoarthritis, testing new chemical modifications to improve joint retention...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to establish a new "microphysiological joint-on-chip" system for the study of arthritic diseases and rapid testing of treatment candidates. The $618,629 award, effective from August 15, 2024 to July 31, 2029, will fund the development of human-derived biomaterial inks and...
This $548,828 Project Grant was awarded on September 21, 2023 by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant was awarded to Knoubis Bio Inc., a for-profit organization based in California, to support research on a non-immunosuppressive disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis. The project aims to develop a new therapeutic approach...
This $139,895 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support research at Brigham & Women's Hospital Inc. to investigate the role of "trained immunity" in linking inflammatory arthritis and cardiovascular disease development. The research aims to determine whether inflammatory responses in rheumatoid arthritis induce trained...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $206,023 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to Cornell University to investigate mechanotransduction pathways in injured cartilage. The research aims to determine how local peak strain magnitude and manipulation of calcium-dependent signaling or mitochondrial bioenergetics affect the distribution of chondrocyte phenotypes after impact injury. This 2-year...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $501,450 to The Washington University to conduct research on regulating tendon repair using stem cell-derived extracellular vesicles. The study aims to identify the specific subpopulation and active cargo molecules of extracellular vesicles that can enhance tendon healing and avoid...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $735,460 to Vanderbilt University Medical Center to study the role of B cells in the development of psoriatic arthritis (PsA). The research aims to demonstrate how decreases in anti-inflammatory IL-10-producing B regulatory (Breg) cells and increases in pro-inflammatory...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $123,040 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to the University of Kansas Medical Center Research Institute, Inc. (KUMCRI) to investigate the therapeutic role of the NFAT1 transcription factor in osteoarthritis (OA) development. The 5-year project, running from August 1, 2024 to July 31, 2029, aims to evaluate the potential of NFAT1 as a therapeutic target...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $526,174 to Duke University to engineer heterocellular human skeletal muscle tissues. The goal is to recreate and study the native stem cell niche function of healthy skeletal muscle, which is critical for its regenerative capacity. By incorporating capillary networks and functional...